414 related articles for article (PubMed ID: 25619440)
1. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.
Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
Thromb Res; 2015 Mar; 135(3):554-60. PubMed ID: 25619440
[TBL] [Abstract][Full Text] [Related]
2. Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage.
Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
J Thromb Haemost; 2015 Dec; 13(12):2220-6. PubMed ID: 26447393
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers.
Levy JH; Moore KT; Neal MD; Schneider D; Marcsisin VS; Ariyawansa J; Weitz JI
J Thromb Haemost; 2018 Jan; 16(1):54-64. PubMed ID: 29106076
[TBL] [Abstract][Full Text] [Related]
4. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
[TBL] [Abstract][Full Text] [Related]
5. Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage.
Herzog E; Kaspereit F; Krege W; Doerr B; Mueller-Cohrs J; Pragst I; Morishima Y; Dickneite G
Anesthesiology; 2015 Feb; 122(2):387-98. PubMed ID: 25419685
[TBL] [Abstract][Full Text] [Related]
6. Favorable outcome of rivaroxaban-associated intracerebral hemorrhage reversed by 4-factor prothrombin complex concentrate: impact on thrombin generation.
Kauffmann S; Chabanne R; Coste A; Longeras F; Sinegre T; Schmidt J; Samama CM; Constantin JM; Lebreton A
A A Case Rep; 2015 Jun; 4(11):151-4. PubMed ID: 26035221
[TBL] [Abstract][Full Text] [Related]
7. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
Zahir H; Brown KS; Vandell AG; Desai M; Maa JF; Dishy V; Lomeli B; Feussner A; Feng W; He L; Grosso MA; Lanz HJ; Antman EM
Circulation; 2015 Jan; 131(1):82-90. PubMed ID: 25403645
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model.
Herzog E; Kaspereit FJ; Krege W; Doerr B; van Ryn J; Dickneite G; Pragst I
Thromb Res; 2014 Sep; 134(3):729-36. PubMed ID: 25084749
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo.
Rayatdoost F; Deventer K; Rossaint R; Schöchl H; Grottke O
Br J Anaesth; 2024 Feb; 132(2):251-259. PubMed ID: 38030550
[TBL] [Abstract][Full Text] [Related]
10. In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate.
Barco S; Whitney Cheung Y; Coppens M; Hutten BA; Meijers JC; Middeldorp S
Br J Haematol; 2016 Jan; 172(2):255-61. PubMed ID: 26488126
[TBL] [Abstract][Full Text] [Related]
11. Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate.
Lipari L; Yang S; Milligan B; Blunck J
Am J Emerg Med; 2020 Dec; 38(12):2641-2645. PubMed ID: 33041150
[TBL] [Abstract][Full Text] [Related]
12. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
[TBL] [Abstract][Full Text] [Related]
13. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
Perzborn E; Heitmeier S; Laux V; Buchmüller A
Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
[TBL] [Abstract][Full Text] [Related]
14. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
[TBL] [Abstract][Full Text] [Related]
15. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ
J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
Schenk B; Würtinger P; Streif W; Sturm W; Fries D; Bachler M
Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677
[TBL] [Abstract][Full Text] [Related]
17. Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation.
van Ryn J; Schurer J; Kink-Eiband M; Clemens A
Anesthesiology; 2014 Jun; 120(6):1429-40. PubMed ID: 24714118
[TBL] [Abstract][Full Text] [Related]
18. In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra.
Brinkman HJM; Zuurveld M; Meijers JCM
Res Pract Thromb Haemost; 2022 Jul; 6(5):e12775. PubMed ID: 35928523
[TBL] [Abstract][Full Text] [Related]
19. Utilization of 4-Factor Prothrombin Complex Concentrate for Reversal of Oral Factor Xa Inhibitor-Associated Acute Major Bleeding: A Case Series.
Reynolds TR; Gilbert BW; Hall KM
J Pharm Pract; 2021 Oct; 34(5):755-760. PubMed ID: 32089040
[TBL] [Abstract][Full Text] [Related]
20. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.
Castillo R; Chan A; Atallah S; Derry K; Baje M; Zimmermann LL; Martin R; Groysman L; Stern-Nezer S; Minokadeh A; Nova A; Huang W; Cang W; Schomer K
J Thromb Thrombolysis; 2021 Jan; 51(1):151-158. PubMed ID: 32500220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
